Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VM 1.0 is an electronic nicotine delivery system (ENDS) developed by Philip Morris Products S.A. as part of its portfolio of potentially reduced-risk products. It is an aerosol generator that utilizes a nicotine-containing liquid, designed to deliver nicotine via inhalation without the combustion of tobacco. The device is engineered to provide a nicotine pharmacokinetic profile similar to that of conventional cigarettes, aiming to satisfy the cravings of adult smokers while reducing exposure to harmful combustion byproducts. Nicotine, the active component, acts as an agonist at nicotinic acetylcholine receptors (nAChRs) in the brain, stimulating the reward system. Clinical studies, such as the crossover pharmacokinetic study mentioned, evaluate the efficiency and safety of nicotine delivery compared to traditional smoking.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VM 1.0.